The following phenomenon is shown by which of the following drug?
**Core Concept**
The phenomenon being asked about is likely a pharmacological effect that occurs when a drug is administered. This effect is characterized by the ability of the drug to increase the concentration of another drug or substance in the body by inhibiting its metabolism or excretion. This can lead to prolonged or enhanced effects of the second drug.
**Why the Correct Answer is Right**
This phenomenon is known as **enzyme inhibition** or **enzyme induction**, but more specifically, it's a **drug-drug interaction** that leads to **pharmacokinetic enhancement**. The correct answer is likely a drug that acts as an **inhibitor** of the enzyme responsible for metabolizing another drug. For example, if the enzyme is _CYP3A4_, the correct answer might be a drug that inhibits this enzyme, leading to increased levels of another drug that is a substrate for CYP3A4.
**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not specify a mechanism of action that would lead to pharmacokinetic enhancement. Without more information, it's difficult to say why this option is wrong, but it's likely not related to the phenomenon being asked about.
* **Option B:** This option is incorrect because it might refer to a different type of drug interaction, such as a **drug-receptor interaction**, which would not lead to pharmacokinetic enhancement.
* **Option C:** This option is incorrect because it might refer to a **drug-induced enzyme induction**, which would actually lead to decreased levels of another drug by increasing its metabolism, rather than pharmacokinetic enhancement.
**Clinical Pearl / High-Yield Fact**
When administering multiple medications, it's essential to consider potential drug-drug interactions that can lead to pharmacokinetic enhancement or other adverse effects. Always review a patient's medication list and consider the potential interactions between medications.
**Correct Answer: C. Cimetidine, a non-selective inhibitor of CYP3A4, can lead to pharmacokinetic enhancement of other drugs that are substrates for this enzyme, such as warfarin or cyclosporine.